Citadel Advisors LLC Buys New Position in Syros Pharmaceuticals Inc (SYRS)

Citadel Advisors LLC bought a new position in shares of Syros Pharmaceuticals Inc (NASDAQ:SYRS) in the second quarter, Holdings Channel reports. The fund bought 18,207 shares of the company’s stock, valued at approximately $186,000.

Other hedge funds have also recently modified their holdings of the company. Alps Advisors Inc. acquired a new position in shares of Syros Pharmaceuticals during the second quarter worth $483,000. JPMorgan Chase & Co. lifted its position in Syros Pharmaceuticals by 13.9% in the first quarter. JPMorgan Chase & Co. now owns 374,513 shares of the company’s stock valued at $4,861,000 after acquiring an additional 45,715 shares during the last quarter. Northern Trust Corp lifted its position in Syros Pharmaceuticals by 35.0% in the first quarter. Northern Trust Corp now owns 181,090 shares of the company’s stock valued at $2,351,000 after acquiring an additional 46,927 shares during the last quarter. BlackRock Inc. lifted its position in Syros Pharmaceuticals by 61.7% in the first quarter. BlackRock Inc. now owns 929,537 shares of the company’s stock valued at $12,066,000 after acquiring an additional 354,591 shares during the last quarter. Finally, Redmile Group LLC lifted its position in Syros Pharmaceuticals by 159.3% in the first quarter. Redmile Group LLC now owns 1,652,240 shares of the company’s stock valued at $21,446,000 after acquiring an additional 1,015,008 shares during the last quarter. Hedge funds and other institutional investors own 60.70% of the company’s stock.

Shares of SYRS opened at $11.83 on Thursday. Syros Pharmaceuticals Inc has a 1-year low of $6.30 and a 1-year high of $17.62. The firm has a market capitalization of $426.40 million, a P/E ratio of -5.55 and a beta of -2.00.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its earnings results on Friday, August 10th. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.07. The business had revenue of $0.38 million during the quarter, compared to analysts’ expectations of $1.33 million. equities analysts predict that Syros Pharmaceuticals Inc will post -1.85 EPS for the current year.

A number of equities research analysts recently weighed in on the stock. BidaskClub cut shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, September 13th. Zacks Investment Research raised shares of Syros Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a research report on Friday, August 10th. HC Wainwright reissued a “hold” rating and issued a $10.00 price target on shares of Syros Pharmaceuticals in a research report on Wednesday, August 8th. Cann reissued a “buy” rating and issued a $26.00 price target on shares of Syros Pharmaceuticals in a research report on Tuesday, August 7th. Finally, Cowen reissued a “buy” rating on shares of Syros Pharmaceuticals in a research report on Tuesday, July 17th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company’s stock. Syros Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $21.00.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

Featured Article: Intrinsic Value and Stock Selection

Want to see what other hedge funds are holding SYRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syros Pharmaceuticals Inc (NASDAQ:SYRS).

Institutional Ownership by Quarter for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply